Leukemia

Latest News

The FDA has asked tambiciclib’s developer to start a trial investigating the combination in front-line acute myeloid leukemia.
Tambiciclib Plus Ven/Aza Met All Primary End Points in R/R AML Trial

July 16th 2025

The FDA has asked tambiciclib’s developer to start a trial investigating the combination in front-line acute myeloid leukemia.

FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML
FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML

July 10th 2025

Current data support prospective studies comparing IDH-triplet vs IDH-doublet therapies among patients with IDH-mutant acute myeloid leukemia.
IDH Triplet Therapy Shows Excellent Outcomes in IDH-Mutant AML

July 7th 2025

The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.
FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML

June 25th 2025

Bexobrutideg Achieves High Objective Response Rate in Heavily Pretreated R/R CLL
Bexobrutideg Achieves High Objective Response Rate in Heavily Pretreated R/R CLL

June 18th 2025

Latest CME Events & Activities

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

View More

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

View More

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

View More

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Community Practice Connections™: Selecting and Sequencing Therapy for Patients with DLBCL in an Era of Expanding Options

View More

BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD

View More

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

View More

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

View More